| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701082 | European Journal of Surgical Oncology (EJSO) | 2017 | 8 Pages |
Abstract
Sarcopenia was not predictive of OS or major complications in ovarian cancer patients undergoing primary debulking surgery. However a strong trend towards a survival disadvantage for patients with sarcopenia was seen. Future prospective studies should focus on interventions to prevent or reverse sarcopenia and possibly increase ovarian cancer survival. Complete cytoreduction remains the strongest predictor of ovarian cancer survival.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
I.J.G. Rutten, J. Ubachs, R.F.P.M. Kruitwagen, D.P.J. van Dijk, R.G.H. Beets-Tan, L.F.A.G. Massuger, S.W.M. Olde Damink, T. Van Gorp,